Also trades as: GLPG.BR (BRU)
GLPG NASDAQ
Galapagos N.V.
1W: -1.2%
1M: -1.4%
3M: -16.2%
YTD: -15.1%
1Y: -2.3%
3Y: -33.6%
5Y: -63.4%
$27.98
Last traded 2026-06-04 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
#?
of ?
Biotechnology
Technical Signal Map
2 Bullish
1 Neutral
7 Bearish
GLPG
$1.8B
Galapagos N.V.
N/A
0
LKFT.AS
$2.1B
Lakefront Biotherapeutics
BULLISH
+58
LKFT
$1.9B
Lakefront Biotherapeutics N.V.
BULLISH
+58
ALEMS.BR
$20M
European Medical Solutions
LEAN BEAR
-26
HYL.BR
$120M
Hyloris Pharmaceuticals S.A.
BEARISH
-66
CYAD.BR
$10M
Celyad Oncology S.A.
BEARISH
-84
UCB.BR
$45B
UCB S.A.
BEARISH
-91
TUB.BR
$7.6B
Financière de Tubize S.A.
BEARISH
-91
OXUR.BR
—
Oxurion N.V.
BEARISH
-91
AGMB
$430M
AgomAb Therapeutics N.V. American Depositary Shares
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| GLPG Galapagos N.V. | $1.8B | 2.8 | 16.3 | 146.1 | 223.6 | 262.2 | 5 | N/A | -2.3 |
| LKFT.AS Lakefront Biotherapeutics | $2.1B | — | — | — | — | — | — | BULLISH | — |
| LKFT Lakefront Biotherapeutics N.V. | $1.9B | — | — | — | — | — | — | BULLISH | — |
| ALEMS.BR European Medical Solutions | $20M | 8.5 | 21.5 | 14.2 | 4.9 | 37.5 | 8 | LEAN BEAR | -17.0 |
| HYL.BR Hyloris Pharmaceuticals S.A. | $120M | -18.5 | -20.2 | -46.3 | -106.5 | 13.6 | 4 | BEARISH | -35.4 |
| CYAD.BR Celyad Oncology S.A. | $10M | 2.7 | -114.8 | -1438.4 | 64357.1 | 102.9 | 4 | BEARISH | -29.5 |
| UCB.BR UCB S.A. | $45B | 17.7 | 34.2 | 23.1 | 26.0 | 44.5 | 8 | BEARISH | 2.2 |
| TUB.BR Financière de Tubize S.A. | $7.6B | 79.0 | 9.9 | -0.3 | — | -99.3 | 6 | BEARISH | 9.1 |
| OXUR.BR Oxurion N.V. | — | -0.0 | 27.7 | 272.3 | -457.8 | -35.0 | 2 | BEARISH | -93.3 |
| AGMB AgomAb Therapeutics N.V. American Depositary Shares | $430M | — | — | — | — | — | — | BEARISH | — |
| GLPG Galapagos N.V. | $1.8B | 2.8 | 16.3 | 146.1 | 223.6 | 262.2 | 5 | N/A | -2.3 |
| LKFT.AS Lakefront Biotherapeutics | $2.1B | — | — | — | — | — | — | BULLISH | — |
| LKFT Lakefront Biotherapeutics N.V. | $1.9B | — | — | — | — | — | — | BULLISH | — |
| ALEMS.BR European Medical Solutions | $20M | 8.5 | 21.5 | 14.2 | 4.9 | 37.5 | 8 | LEAN BEAR | -17.0 |
| HYL.BR Hyloris Pharmaceuticals S.A. | $120M | -18.5 | -20.2 | -46.3 | -106.5 | 13.6 | 4 | BEARISH | -35.4 |
| CYAD.BR Celyad Oncology S.A. | $10M | 2.7 | -114.8 | -1438.4 | 64357.1 | 102.9 | 4 | BEARISH | -29.5 |
| UCB.BR UCB S.A. | $45B | 17.7 | 34.2 | 23.1 | 26.0 | 44.5 | 8 | BEARISH | 2.2 |
| TUB.BR Financière de Tubize S.A. | $7.6B | 79.0 | 9.9 | -0.3 | — | -99.3 | 6 | BEARISH | 9.1 |
| OXUR.BR Oxurion N.V. | — | -0.0 | 27.7 | 272.3 | -457.8 | -35.0 | 2 | BEARISH | -93.3 |
| AGMB AgomAb Therapeutics N.V. American Depositary Shares | $430M | — | — | — | — | — | — | BEARISH | — |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
GLPG vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F